Assessing Clinical and Dosimetric Benefits of Spot-Scanning Proton Arc Therapy in Ocular Melanoma Treatment

Document Type

Conference Proceeding

Publication Date

10-2024

Publication Title

International Journal of Radiation Oncology, Biology, Physics

Abstract

Purpose/Objective(s): To evaluate the feasibility and dosimetric superiority of spot-scanning proton arc therapy (SPArc) for ocular melanoma, in comparison to Intensity Modulated Proton Therapy Materials/Methods: Six ocular melanoma cases, varying in size (large/ small) and anatomical locations (posterior/anterior/optic disc), were planned with 3-field IMPT (3F-IMPT) and SPArc for dosimetric comparison. With a target dose normalized to 50 cGE, 3.5% range uncertainty were used in both groups for robust optimization. Dose to organs-at risk (OARs) were analyzed. The mean dose averaged linear energy transfer (LETd) were calculated with dose threshold of voxels receiving no less than 20% of the maximum dose. Results: SPArc demonstrated a consistently superior dose distribution compared to 3F-IMPT in all cases. Notably, SPArc achieved improved dose sparing of lens and cornea in tumor situated in the posterior segment and optic disc region, where the lens and cornea were in the beam path. Specifically, for the four cases involving tumors in the posterior segment or optic disc, the median maximum dose (Dmax) to the lens with IMPT and SPArc was 30.61 cGy and 10.62 cGy, respectively. SPArc achieved a 65.3% reduction in the lens's Dmax. A similar outcome was observed for the mean dose (Dmean) to the cornea, with SPArc achieving a 76.7% reduction in the Cornea Dmean. Additionally, SPArc presented an increased LETd within the target area while reducing the LETd in OARs abutting the target. Particularly, the median of mean LETd for tumors was 3.90 keV/mm with IMPT compared to 4.14 keV/mm with SPArc. For the lens, the median of mean LETd was significantly lower with SPArc at 0.60 keV/mm, compared to 1.92 keV/mm with IMPT. Conclusion: As an innovative proton therapy approach, SPArc without utilizing the compensator and blocks or MLCs has demonstrated dosimetric superiority and adaptability in treating ocular melanomas situated in the posterior segment and optic disc region, especially in scenarios where sparing of the lens and cornea is crucial.

Volume

120

Issue

2S

First Page

e737

Comments

ASTRO 2024: 66th Annual Meeting American Society for Radiation Oncology, September 29 - October 2, 2024, Washington, DC

DOI

10.1016/j.ijrobp.2024.07.1621

Link to Full Text

Share

COinS